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The JAK2 V617F mutation is the most common somatic mutation in the classical myeloproliferative
neoplasms (MPNs), present in .95% of cases of polycythemia vera (PV) and ;50% of essential
thrombocythemia (ET) and myelofibrosis (MF).1-4 It is usually the sole identifiable driver mutation in MPNs5
and was recently also identified as a driver of age-related clonal hemopoiesis in healthy individuals.6-9 In
order to investigate the preclinical clonal evolution of MPNs, we identified 12 individuals with a JAK2 V617F
mutant MPN, who 4.6 to 15.2 years previously (median 10.2 years) had also donated blood to register with
the Cyprus Bone Marrow Donor Registry at the Karaiskakio Foundation (Table 1; Figure 1A).
First, we interrogated all 24 samples for 15 myeloid mutation hot spots including JAK2 V617
(supplemental Table 1), using a previously described multiplex polymerase chain reaction/MiSeq
sequencing protocol that reliably detects nucleotide substitutions present at a VAF $0.008.6
Additionally, for 12 samples with sufficient DNA available, we performed targeted DNA capture for all
exons of 41 genes recurrently mutated in myeloid neoplasms (supplemental Table 2) using targeted
capture with custom RNA baits (SureSelect, Agilent Technologies ELID ID: 0735431) followed by
sequencing on Illumina HiSeq 2500. Substitutions and indels were identified and quantified using
Mutation Identification and Analysis Software as described.6,10 Finally, we genotyped archival registry
samples for rs12343867, a single nucleotide polymorphism (C/T) linked to the JAK2 46/1 haplotype
and polymorphisms at the TERT, SH2B3, TET2, MECOM, and MYB genes that are associated with a
predisposition to MPN.11,12 The study was approved by the Cyprus National Bioethics Committee
(EEBK/EP/2014/11) and performed in accordance with the Declaration of Helsinki.
Amplicon sequencing returned a median coverage of 6641 reads per nucleotide at the studied hot spots
(excluding NPM1 exon 12). This confirmed the presence of JAK2 V617F in all 12 diagnostic and 9 of
12 archival samples (supplemental Table 3). The remaining 3 samples were JAK2 V617F negative
at the sensitivity of our assay (VAF$0.008). The only other hot spot mutation identified was SRSF2
P95R in patient P3 (see later). Pull-down sequencing of all exons of 41 genes from 12 samples with
sufficient DNA returned an average coverage of 1978 reads per nucleotide and showed a close
correlation in VAF quantitation for both JAK2 V617F and SRSF2 P95R with amplicon sequencing
(supplemental Table 3).
The JAK2 V617F VAF at MPN diagnosis differed between patients as expected13; however, the average
rate of clonal growth also varied widely, ranging from 0.36% to 6.2% per annum (Figure 1B). Targeted
exon capture from 12 of 24 samples only identified 1 co-mutation with a VAF .0.02, SRSF2 P95R in
patient P3 who had a diagnosis of MF (supplemental Table 3). As this locus was also studied by
amplicon sequencing, we were able to quantify the SRSF2 P95R VAF in both the diagnostic and the
archival sample taken 12.6 years earlier. The MPN diagnostic sample VAFs for JAK2 V617F and SRSF2
P95R were similar (0.37 and 0.41, respectively; supplemental Tables 3 and 4) indicating that they co-
occurred in most cells of the neoplastic clone. However, the archival sample did not harbor JAK2 V617F
(or did so at a level below the sensitivity of our assay) but did harbor the SRSF2 P95R at a VAF of 0.06
indicating this was the clone-founding mutation.
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We and others reported that JAK2 V617F was a common driver of
clonal hematopoiesis6-9; however, although JAK2 V617F clonal
hematopoiesis is likely to be the ancestor of most MPNs, our
understanding of the latency and rate of clonal expansion of JAK2
V617F–positive clones are not well understood. Our findings
demonstrate that although additional driver mutations can acceler-
ate preclinical clonal expansion of JAK2 V617F clones, the process
is highly variable even between individuals whose clones harbor
JAK2 V617F as the sole identifiable driver and who represent the
majority of MPN patients.14
A recent study used ultrasensitive sequencing to show that clonal
hematopoiesis driven by acute myeloid leukemia (AML)–associated
mutations was ubiquitous among healthy adults aged 50 to 60
years.15 Interestingly, most clones identified in this study were
associated with loss-of-function mutations in DNMT3A and TET2,
and although most persisted over long periods (.10 years), they
usually exhibited only modest expansion if any. However, in contrast
to studies looking at larger numbers of people with lower assay
sensitivities,6-9 this study did not identify JAK2 mutant clones in any
of its 20 participants.15 It is therefore possible that JAK2 V617F,
a hot spot mutation that relies on a G.T transversion that is
uncommon in myeloid malignancies,16 is acquired less often but has
a more pronounced effect on clonal growth than many other
mutations. Nevertheless, it should be noted that the high rates of
clonal growth in our study were observed in individuals that (1) were
younger than the average MPN patient (as they were identified
because they were registered stem cell donors) and (2) did actually
go on to develop MPN and are therefore unlikely to be characteristic
of the general behavior of JAK2 V617F clones. Additionally, there is
a possibility that some of these clones may not have been the same
from clonal hematopoiesis to MPN diagnosis, as MPN patients can
sometimes harbor .1 JAK2 V617F clone.17 Nevertheless, clonal
expansion rates varied dramatically even among the 12 individuals
studied here. As certain germ line polymorphisms are associated
with an increased risk of developing both JAK2 V617F–driven
clonal hematopoiesis and MPN,11,12,17,18 we genotyped our patients
for these (supplementary Table 4). In our small group of patients,
we observed a possible association between the JAK2 46/1 risk
haplotype (C) and the average annual rise in JAK2 V617F VAF. In
fact, the 4 fastest-expanding clones were either CC homozygous
in the germ line (P2 and P4) or through somatic loss of hetero-
zygosity (P1), or had a second driver mutation (P3). These ob-
servations suggest that the 46/1 haplotype may influence the rate
of expansion of established JAK2 V617F mutant clones and that
loss of heterozygosity involving the risk haplotype may further
expedite clonal expansion. These findings need to be verified in
larger studies.
Interestingly, 1 of our patients acquired JAK2 V617F after SRSF2
p95R, and this was followed by a clonal sweep and the develop-
ment of MF.12 years later. Clonal hematopoiesis driven by mutant
SRSF2 is very rare before the age of 70 years,6 yet this individual
harbored a significant SRSF2 P95R clone (VAF 0.06) aged only
40 years old. A recent study of 182 MF patients identified many
with JAK2 V617F and SRSF2 P95 co-mutation, including several
aged ,70 years (n 5 21, age range 39-84 years).19 Taken
together, these observations suggest that younger individuals with
SRSF2-mutant clonal hematopoiesis may be at a high risk of
progression to a hematological neoplasm.
Our study demonstrates that JAK2 V617F neoplasms develop from
clonal hematopoiesis over many years, sometimes over more than
a decade. Although co-mutations in other myeloid genes may
accelerate the rate of JAK2 V617F–driven clonal expansion, the
rate can be highly variable even among those without co-mutations
as demonstrated at least by the 7 of our 12 patients studied using
targeted capture of 41 myeloid genes. Our findings suggest that
heritable polymorphisms such as the JAK2 46/1 haplotype may
have a role,20 but this will need to be confirmed in larger future
studies and it is probable that nongenetic factors may also be at
play. Our ability to predict clonal growth and by extension forecast
the likelihood of progression of JAK2 V617F clonal hematopoiesis
to MPN remains limited, and our study contributes to the under-
standing of this process. In order to better advise individuals with
clonal hematopoiesis of their prognosis and to identify those that
could benefit from current or future therapies, larger studies are
required to define the variables influencing clonal expansion
whether they are heritable vs environmental or cell-intrinsic vs cell-
extrinsic and related to the hematopoietic microenvironment.21,22
Table 1. Participant characteristics
Patient ID Age at MPN diagnosis (y) Sex Diagnosis WBC count (3106/L) Hb (g/L) Platelet count (3106/L) Time between samples (y)
P1 53.6 F PV 17.3 194 550 10.1
P2 24.2 F PV n/a n/a n/a 5.5
P3 53.4 F MF 4.2 112 130 12.6
P4 24.5 M ET 8.4 15.6 600 4.6
P5 58.7 F ET 8.94 142 637 14.5
P6 40.6 F PV 7.7 168 602 6.8
P7 68.2 M MF 8.1 81 74 15.2
P8 33 M ET 10.3 149 776 12.1
P9 43.2 M ET 12.1 148 793 9.4
P10 66.9 F PV 7.6 154 830 14.7
P11 58.4 M PV 12.7 220 423 10.3
P12 27 F ET 5.1 135 750 4.6
F, female; Hb, hemoglobin concentration; M, male; MF, idiopathic myelofibrosis; n/a, not available; WBC, white blood cell.
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The full-text version of this article contains a data supplement.
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Figure 1. Preclinical expansion of JAK2 V617F clones in 12 MPN patients. (A) Schema of blood sample collection from 12 individuals at the time of registration as stem cell
donors at the Cyprus Bone Marrow Donor Registry and at the time they were diagnosed with MPN 4.6 to 15.2 years later. (B) Variant allele fraction (VAF) sizes of JAK2
V617F–positive clones at the 2 time points against the age of participants at the time. The specific diagnosis is indicated in brackets next to each patient’s ID, and the average annual
rise in JAK2 V617F VAF is indicated in the upper right quadrant of each plot. Samples P3, P7, and P8 had no detectable JAK2 V617F at donor registration. The VAF rise for SRSF2
P95R in patient P3 is show in red.
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